Oncology Xagena
Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor ( ALKi ), shrank tumours ( overall response rate; ORR: 50% ...
Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...
Final, mature progression-free survival ( PFS ) from the global phase III ALEX study of Alectinib ( Alecensa ) vs Crizotinib ( Xalkori ) in untreated, advanced / metastatic anaplastic lymphoma kinase- ...
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib ( Xalkori ) in treatment-naive ALK-positive non-small-cell lung c ...
Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status in patients with advanced ALK immunohistochemistry ( ...
